Skip to main content

Table 1 Studies That Assessed Impact of PSMA PET/CT on SRT Planning

From: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

Author Year n PSA (ng/ml) Median (range) PSMA+ Extrapelvic PSMA+ Any SRT Planning Change SRT Considered Futile
Shakespeare 2015 18 1.1 (0.017–20.4) NA NA 46% NA
van Leeuwen 2015 70 0.2 (0.05–0.99) 55% 6% 35% 7%
Sterzing 2016 42 2.8 (0.16–113) 60% NA 61% NA
Bluemel 2016 45 0.67 (0.10–11.2) 54% 9% 42% 4%
Albisinni 2016 48 2.2 (0.72–6.7) NA NA 76% NA
Schiller 2017 31 0.71 (0.12–14.7) 100% 3% 87% 0%
Henkenberens 2017 39 1.2 (0.3–15.5) 85% 46% 59% 13%
Schmidt-Hegemann 2017 49 0.49 (0.15–6.24) NA 4% 57% NA
Habl 2017 83 0.69 (0.09–14.7) 71% 10% 57% 0%
De Bari 2018 12 0.51 (0.10–1.62) NA NA 17% 8%
Koerber 2018 71 1.2 (0.03–41.24) NA 51% 54% 3%
Frenzel 2018 75 0.2 (0.02–653.2) NA NA 43% NA
Farolfi 2018 119 0.32 (0.20–0.50) 35% 21% 30% 18%
Calais 2018 270 0.48 (0.03–1.0) 49% 13% 19% 12%